☝🏼Happy to have collaborated in the GLOBAL-PAN study led by Omer Karadag. The low prevalence of #PAN necessitates a global effort to clarify its characteristics and outcome 🇹🇷🇨🇦🇺🇸🇲🇽🇯🇵🇬🇧🇸🇮🇸🇪🇮🇹 ACR_Journals Ertugrul Cagri Bolek, MD MSc Peter Merkel Peter Grayson KenWarringtonMD Philip Seo

Upa looked good in trials - what about real world? Josh Baker and colleagues using CorEvitas, LLC: 46% MCID improvement in CDAI and 40% CDAI LDA, regardless of prior TNF exposure, line of tx, or use of csDMARDs. pubmed.ncbi.nlm.nih.gov/38345715/

Our Joint Chat Rheum will be held on Zoom on February 25th at 6 PM EST / 3 PM PST. Join the opportunity to get involved and have discussions. Our Take a Pain Check executives and ambassadors will be leading activities! Use the link in our bio to sign up now! #TAPC #Awareness

Clinically meaningful improvements in pain (40%) and physical function (30%) after 6 months in patients with PsA treated with guselkumab. Notable that ~90% of these pts were treatment refractory. From Penn's AlexisO and colleagues pubmed.ncbi.nlm.nih.gov/38417434/

Benralizumab noninferior to mepolizumab for induction in patients with relapsing/refractory eGPA. Great to have a new med in the arsenal for this tough disease. From Peter Merkel and MANDARA study group Penn Medicine Penn Vasculitis Foundation www-nejm-org.proxy.library.upenn.edu/doi/10.1056/NE…

Attention 1st year Rheum Fellows— UPenn Medicine puts on an Annual conference just for you! It’s free for in person attendance and $75 if virtual. I looked at the speakers list— impressive Dr Peter Merkel, ⁦Ethan Craig⁩ ⁦AlexisO⁩! eventbrite.com/e/31st-annual-…

Case series of 8 pts with SSc receiving ICI for cancer dx - iRAE common, but in this series ICI well tolerated. Johns Hopkins Rheumatology and Penn Rheum collab! Seminars in Arthritis and Rheumatism Dana DiRenzo Jonathan Kotzin Laura Cappelli pubmed.ncbi.nlm.nih.gov/38733668/

Fibromyalgia: a common comorbidity in PsA - up to 11% of patients fulfill criteria, and over 1 in 5 fulfill definition of widespread pain. Really complicates assessment of disease activity, esp when it comes to enthesitis! AlexisO pubmed.ncbi.nlm.nih.gov/38736168/

Dana DiRenzo PennRheum presents on the use of #Ultrasound in salivary glands #Sjogrens US has utility on longitudinal assessment #RhMSUS #POCUS #RhUS

Dana DiRenzo, M.D. of PennRheum at the USSONAR MULTI TRACK ULTRASOUND COURSE in her element teaching Salivary Gland #sjogrens ultrasound. As she says, “An easy, quick tool to assess disease activity in Sjogren’s Syndrome, but be cautious about lymphomas.” #pocus #rheum

Dana DiRenzo PennRheum presents on the use of #Ultrasound in salivary glands #Sjogrens US has utility on longitudinal assessment! #RhMSUS #RhUS #POCUS

Dana DiRenzo PennRheum presents on the use of #Ultrasound in salivary glands #Sjogrens US has utility on longitudinal assessment! #RhUS #RhMSUS

Stress and trauma are associated with worse PRO's in SLE, and perceived stress with greater SLE activity. Attn to improving positive and reducing negative psychosocial factors may be beneficial for stress in these pts. Dr. Kim Dequattro Penn Medicine pubmed.ncbi.nlm.nih.gov/38754905/

Our latest findings: Mislocalized TREX1 causes DNA damage in flies, mice, & humans with RVCL, a mimic of lupus and radiation injury—plus high odds of breast cancer ⁦PennRheum⁩ ⁦Brain Research Institute, Niigata Univ⁩ ⁦Penn Medicine⁩ ⁦Nature Communications⁩ nature.com/articles/s4146…

And now—with the help of amazing collaborators Penn Medicine —we can convert the toxic TREX1 protein (dominant, truncated TREX1 mutant) into the full-length TREX1 using a modified CRISPR approach. The next challenge is optimizing delivery to the blood vessel wall, but we believe

Vessel wall imaging in GCA is a promising modality for diagnosis. New pub from Dr. Rhee from Penn Medicine along with VCRC collabs outlines standardized protocol and scoring for these images. pubmed.ncbi.nlm.nih.gov/39331619/